RCT-1100 is under clinical development by Recode Therapeutics and currently in Phase I for Primary Ciliary Dyskinesia. According to GlobalData, Phase I drugs for Primary Ciliary Dyskinesia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the RCT-1100 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RCT-1100 overview
RCT-110 is under development for the treatment of primary ciliary dyskinesia. It is administered through oral inhalational route using nebulizer. The drug candidate is being developed based Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery platform which enables organ specific delivery of RNAs and DNAI1 protein payloads.
Recode Therapeutics overview
Recode Therapeutics is a biotechnology company that focuses on developing therapeutics for genetically defined diseases that currently lack treatment options. Its main activities focus on creating precision genetic medicines using their proprietary selective organ targeting (SORT) lipid nanoparticle (LNP) platform. The company’s products include investigational mRNA-based therapies for conditions such as primary ciliary dyskinesia and cystic fibrosis. ReCode’s products are designed for patients with rare genetic disorders, with potential applications across various fields, including muscular, central nervous system, liver, infectious disease, and oncology indications. ReCode Therapeutics is headquartered in Menlo Park, California, the US.
For a complete picture of RCT-1100’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
